Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Manic State Clear all
Completed Phase 4 Interventional Results available

Study in Adolescents With Schizophrenia or Bipolar Disorder

NCT00982020
View directory record Official record
Conditions
Bipolar I Disorder, Schizophrenia
Interventions
Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
Drug · Behavioral
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Lauderhill, Florida • Bloomfield Hills, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 4 Interventional

Lamictal As Add on Treatment in Mixed States of Bipolar Disorder

NCT00223509
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lamotrigine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
13 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 29, 2026, 5:56 PM EDT
Terminated Phase 4 Interventional

DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder

NCT02623504
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Carbamazepine, Placebo
Drug
Lead sponsor
Validus Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Orlando, Florida • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Decision-Making in Bipolar Disorder

NCT01463111
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Valproate, Lamotrigine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine

NCT00394095
View directory record Official record
Conditions
Bipolar Disorder, Weight Gain
Interventions
Topiramate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Not applicable Interventional Results available

Group-Based Behavioral Therapy Combined With Stimulant Medication for Treating Children With Attention Deficit Hyperactivity Disorder and Impaired Mood

NCT00632619
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Group-based behavior therapy, Stimulant medication therapy, Community-based psychosocial treatment
Behavioral · Drug
Lead sponsor
Florida International University
Other
Eligibility
7 Years to 11 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 29, 2026, 5:56 PM EDT
Completed No phase listed Observational

Understanding Treatment Adherence Among Individuals With Rapid Cycling Bipolar Disorder

NCT00183703
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Beachwood, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

NCT03259555
View directory record Official record
Conditions
Bipolar I Disorder, Manic Episode
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)

NCT01396291
View directory record Official record
Conditions
Bipolar 1 Disorder
Interventions
asenapine, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
30
States / cities
Anaheim, California • Chino, California • Escondido, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Not applicable Interventional

A Study of Spoken Language in Mania

NCT05956340
View directory record Official record
Conditions
Manic Episode, Bipolar I Disorder
Interventions
Research interview
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders

NCT00650611
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
17
States / cities
San Diego, California • Altamonte Springs, Florida • Libertyville, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study

NCT00217165
View directory record Official record
Conditions
Bipolar Disorder, Mania, Bipolar Depression
Interventions
taurine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 68 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

Prevention of Relapse & Recurrence of Bipolar Depression

NCT00961961
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium / Fluoxetine, Lithium / Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

NCT00107731
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
quetiapine fumarate, lithium, divalproex
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • Chula Vista, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 29, 2026, 5:56 PM EDT
Terminated Phase 1 Interventional

Taurine in Adolescents With Bipolar Disorder

NCT00391001
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Taurine
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
13 Years to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Belmont, Massachusetts • Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

NCT07046494
View directory record Official record
Conditions
Bipolar 1 Disorder
Interventions
RAP-219, Placebo
Drug · Other
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Chino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 5:56 PM EDT
Terminated Not applicable Interventional Results available

Accelerated Theta Burst Stimulation for Inpatients With Bipolar Disorder

NCT04058249
View directory record Official record
Conditions
Bipolar Disorder, Manic, Bipolar Disorder I
Interventions
Accelerated intermittent theta-burst stimulation over right DLPFC
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

NCT03573297
View directory record Official record
Conditions
Bipolar I Disorder, Mania, Depression
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
46
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

Quetiapine for Bipolar Disorder and Alcohol Dependence

NCT00457197
View directory record Official record
Conditions
Bipolar Disorder, Alcohol Dependence
Interventions
Placebo, Quetiapine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 29, 2026, 5:56 PM EDT
Recruiting Phase 2 Interventional

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

NCT07288320
View directory record Official record
Conditions
Bipolar I Disorder, Mania
Interventions
NBI-1117568, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 1Phase 2 Interventional

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

NCT00825539
View directory record Official record
Conditions
Schizophrenia
Interventions
AQW051, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 4 Interventional

Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study

NCT00223223
View directory record Official record
Conditions
Memory Loss Associated With Corticosteroid Use, Manic State Associated With Corticosteroid Use
Interventions
Levetiracetam, Keppra
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 29, 2026, 5:56 PM EDT
Completed Phase 4 Interventional

Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder

NCT00034580
View directory record Official record
Conditions
Bipolar Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
21
States / cities
Berkley, California • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 29, 2026, 5:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Psychological Development of Children of Parents With and Without Affective Disorders

NCT00001170
View directory record Official record
Conditions
Bipolar Disorder, Involutional Depression, Mood Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
1,045 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1979 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 5:56 PM EDT